natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the compound is 1-(6-(trans-4-tert-butylcyclohexyloxy)-2-naphthoyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-(6-(trans-4-tert-butilcikloheksiloksi)-2-naftoil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-((6-((4-tert-butylcyclohexylidene)methyl)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-((4-tert-butilcikloheksiliden)metil)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-3-methyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-3-metil-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-4-phenyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-4-fenil-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-perhydro-azepine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-perhidro-azepin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-[7-(trans-4-tert-butyl-cyclohexyloxy)-isoquinolin-3-ylmethyl]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[7-(trans-4-tert-butil-cikloheksiloksi)-izokinolin-3-ilmetil]-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-((6-(cyclopentyloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(ciklopentiloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-((6-(tetrahydro-2H-pyran-4-yloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(tetrahidro-2H-piran-4-iloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The method of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-piperidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-piperidin-2-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
wherein the connecting tab (16) is separated from the rest of the sealing flap (5) by a fold line (19); 
pri čemu je spojni jezičac (16) linijom (19) savijanja odvojen od ostatka brtvenog kapka (5);
A package as claimed in Claim 1, wherein the fold line (19) is formed by cutting or removing material from the sealing flap (5). 
Pakiranje u skladu sa patentnim zahtjevom 1, naznačeno time što je linija (19) savijanja napravljena isjecanjem ili uklanjanjem materijala iz brtvenog kapka (5).
A package as claimed in Claim 1 or 2, wherein the fold line (19) is continuous and formed by scoring the material of the sealing flap (5). 
Pakiranje u skladu sa patentnim zahtjevom 1 ili 2, naznačeno time što je linija (19) savijanja neprekidna i napravljena je urezivanjem u materijal brtvenog kapka (5).
A package as claimed in Claim 1 or 2, wherein the fold line (19) is discontinuous and formed by cutting through the material of the sealing flap (5). 
Pakiranje u skladu sa patentnim zahtjevom 1 ili 2, naznačeno time što je linija (19) savijanja isprekidana i napravljena je presijecanjem kroz materijal brtvenog kapka (5).
A package as claimed in Claim 1 or 2, wherein the fold line (19) is discontinuous and formed by scoring the material of the sealing flap (5). 
Pakiranje u skladu sa patentnim zahtjevom 1 ili 2, naznačeno time što je linija (19) savijanja isprekidana i napravljena je urezivanjem u materijal brtvenog kapka (5).
A package as claimed in any one of Claims 1 to 6, wherein an outer surface of the connecting tab (16) of the sealing flap (5) is glued by spots of permanent glue (17a) to the inner surface of the lid (7). 
Pakiranje u skladu sa bilo kojim patentnim zahtjevom 1 do 6, naznačeno time što je vanjska površina spojnog jezičca (16) brtvenog kapka (5) zalijepljena točkicama stalnog ljepila (17a) na unutarnju površinu poklopca (7).
A package as claimed in any one of Claims 1 to 9, wherein the distance (D) between the fold line (19) and the re-stick glue (17b) on the sealing flap (5) is at least 1 mm. 
Pakiranje u skladu sa bilo kojim patentnim zahtjevom 1 do 9, naznačeno time što je udaljenost (D) između linije (19) savijanja i ljepila (17b) za višekratno lijepljenje na brtvenom kapku (5) najmanje 1 mm.
The compound for use according to claim 3, wherein the mitochondrial disease is selected from the group consisting of Leber's hereditary optic neuropathy (LHON), autosomal dominant optic atrophy (DOA), macular degeneration and glaucoma. 
Spoj za upotrebu prema zahtjevu 3, naznačen time, da se mitohondrijska bolest bira iz skupine koju čine Leberova hereditarna optička neuropatija (LHON), autosomna dominantna optička atrofija (DOA), makularna degeneracija i glaukom.
• a co-crystal comprising (+)-tramadol either as a free base or as its physiologically acceptable salt and (R)-naproxen; 
• ko-kristala koji sadrže (+)-tramadol bilo kao slobodnu bazu ili kao fiziološki prihvatljivu sol i (R)-naproksen;
adding the solution of (b) to the solution of (a) and mixing them; 
proizvoljno dodavanje otopine (b) u otopinu (a) i njihovo miješanje;
and R21, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
i R21, zajedno sa atomom dušika za koji su vezani, formiraju nesupstituirani ili supstituirani heterociklični prsten sa 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
A compound of claim 1 having formula IIB, or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein R13 is -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O) NR20R21 or -(CH2)1-3-R23. 
Farmaceutski sastav prema patentnom zahtjevu 2 koji sadrži spoj formule IIB ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, gdje R13 je -(CH2)0-3CR17R18NR20R21 ili -(CH2)0-3CR17R18NR17C(O)NR20R21.
A compound of claim 1 of formula IIC: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav prema patentnom zahtjevu 1, gdje spoj formule IIB je spoj formule IIC: [image] ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, gdje:
and R21, taken together with the nitrogen atom to which they are attached, form a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
i R21, zajedno sa atomom dušika za koji su vezani, formiraju heterociklični prsten sa 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
The pharmaceutical composition of claim 1 wherein the compound of formula IIB is the compound of formula IIBa or a pharmaceutically acceptable salt, solvate, and/or ester thereof. 
Farmaceutski sastav prema zahtjevu 1, gdje spoj formule IIB je spoj formule IIBa: [image] ili njegovu farmaceutski prihvatljivu sol, solvat i/ili ester.
The pharmaceutical composition of any one of claims 1 to 8, wherein the composition comprises two or three additional therapeutic agents selected from HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, and HIV integrase inhibitors. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva od 1 do 8, gdje sastav sadrži dva ili tri dodatna terapijska agensa izabrana od inhibitora HIV proteaze, ne-nukleozidnih inhibitora HIV reverzne transkriptaze, nukleozidnih inhibitoria HIV reverzne transkriptaze, nukleotidnih inhibitoria HIV reverzne transkriptaze i inhibitora HIV integraze.
The pharmaceutical composition of any one of claims 1 to 9, wherein the at least one additional therapeutic agent is selected from the group consisting of HIV protease inhibiting compounds. 
Farmaceutski sastav prema bilo kojem od patentnih zahtjeva od 1 do 9, gdje je najmanje jedan dodatni terapijski agens izabran iz grupe koja se sastoji od spojeva koji inhibiraju HIV proteaze.
A process as in any of claims 32 and 33 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 5, naznačena time što je farmaceutski prihvatljiva kiselina metansulfonska kiselina, a sadržaj odgovarajućih nečistoća formule (IIa) ili (IIb) u obliku soli s metansulfonskom kiselinom je niži od 0,01% (težinski).
An oral pharmaceutical composition, which is a core tablet composition, comprising: 
Oralni farmaceutski sastav koji predstavlja sastav jezgre tablete, naznačen time, da obuhvaća sljedeće:
povidone present in a range of 4 to 9 per cent by weight; 
povidon koji je prisutan u rasponu od 4 do 9 masenih postotaka;
sodium starch glycolate present in a range of 2 to 8 per cent by weight; 
natrijev škrobni glikolat koji je prisutan u rasponu od 2 do 8 masenih postotaka;
The oral pharmaceutical composition of claim 1 wherein: 
Oralni farmaceutski sastav prema zahtjevu 1, naznačen time, da:
said sodium starch glycolate is present in a range of 3.5 to 5.5 per cent by weight; 
je navedeni natrijev škrobni glikolat prisutan u rasponu od 3,5 do 5,5 masenih postotaka;
An oral pharmaceutical composition, which is a tablet composition, comprising: 
Oralni farmaceutski sastav koji predstavlja sastav tablete, naznačen time, da obuhvaća sljedeće:
haloalkyl is a lower alkyl group, an alkenyl group, an alkynyl group, a bridged cycloalkyl group, a cycloalkyl group to which is appended one or more halogens; 
haloalkil je niža alkilna skupina, alkenil skupina, alkinil skupina, premoštena cikloalkil skupina, cikloalkil skupina na koju se dodaje jedan ili više halogena;
alkyl is an unbroken non-cyclic chain of carbon atoms that may be branched, unbranched, substituted with other chemical groups such as lower alkyl, hydroxyl, ester, amidyl, oxo, carboxyl, carboxamido, halo, cyano, nitrate, nitrite, thionitrate, thionitrite, sulfhydryl and amino, or unsubstituted; 
alkil je neprekinuti ne-ciklički lanac ugljikovih atoma koji može biti razgranat, nerazgranat, supstituiran s drugim kemijskim skupinama kao što su niži alkil, hidroksil, ester, amidil, okso, karboksil, karboksamido, halo, cijano, nitrat, nitrit, tionitrat, tionitrit, sulfhidril i amino, ili nesupstituiran;
alkenyl is a branched or straight chain C2-C10 hydrocarbon that can comprise one or more carbon-carbon double bonds; 
alkenil je razgranati ili ravnolančani C2-C10 ugljikovodik koji može sadržavati jednu ili više dvostrukih veza ugljik-ugljik;
alkynyl is an unsaturated acyclic C2-C10 hydrocarbon that can contain one or more carbon-carbon triple bonds; 
alkinil je nezasićeni aciklički C2-C10 ugljikovodik koji može sadržavati jednu ili više trostrukih veza ugljik-ugljik;
and wherein lower alkyl is as defined in claim 1. 
i pri čemu niži alkil je kako je definirano u zahtjevu 1.
A composition for use in inhibiting the formation or accumulation of a toxic visual cycle product condition in a subject at risk thereof or afflicted therewith, comprising an effective amount of a compound of claim 1, 5, 6 or 7. The composition for use as claimed in claim 8, wherein said inhibiting occurs in a cell. 
Pripravak za naznačen tima da je za uporabu u inhibiciji formiranja ili akumulacije toksičnih stanja vizualnog cikličkog produkta kod subjekta koji ima rizik od takvog stanja ili pati od njega, koji sadrži djelotvornu količinu spoja prema zahtjevu 1, 5, 6 ili 7.
A composition for use in treating or preventing an ophthalmic condition in a subject at risk thereof or afflicted therewith, comprising an effective amount of a compound of claim 1, 5, 6 or 7. 
Pripravak za uporabu za liječenje ili sprječavanje oftalmičkog stanja kod subjekta koji ima rizik od takvog stanja ili pati od njega, naznačen time da sadrži djelotvornu količinu spoja prema zahtjevu 1, 5, 6 ili 7.
The composition for use as claimed in claim 11, wherein said ophthalmic condition is selected from the group consisting of wet or dry age related macular degeneration (ARMD), retinitis pigmentosa (RP), a retinal or macular dystrophy, Stargardt's disease, Sorsby's dystrophy, autosomal dominant drusen, Best's dystrophy, peripherin mutation associate with macular dystrophy, dominant form of Stargart's disease, North Carolina macular dystrophy, light toxicity, normal vision loss related aging and normal loss of night vision related to aging. 
Pripravak za uporabu kako je zatraženo u zahtjevu 11, naznačen time da se navedeno oftalmičko stanje bira iz skupine koju čine vlažni ili suhi oblik starosne makularne degeneracije (ARMD), retinitis pigmentosa (RP), retinalna ili makularna distrofija, Stargardtova bolest, Sorsbyjeva distrofija, autosomno dominantne druze, Bestova distrofija, mutacije periferina povezane s makularnom distrofijom, dominantni oblik Stargardtove bolesti, makularna distrofija North Carolina, toksičnost svjetlosti, normalni gubitak vida povezan sa starenjem i normalan gubitak noćnog vida povezan sa starenjem.
Compounds corresponding to the general formula: 
Spojevi koji odgovaraju općoj formuli:
X is a halogen atom chosen from fluorine, chlorine and bromine atoms, 
X je atom halogena odabran od atoma fluora, klora i broma,
L represents the following PEG radicals: in which 
L predstavlja slijedeće PEG radikale: [image] [image] u kojima
n represents an integer from 2 to 6, in the form of a base or of an addition salt with an acid or with a base. 
n predstavlja cijeli broj 2 do 6, u obliku baze ili adicijske soli s kiselinom ili s bazom.
Compounds according to Claim 1, characterized in that R1 represents a hydrogen atom, in the form of a base or of an addition salt with an acid or with a base. 
Spojevi prema zahtjevu 1, naznačeni time da R1 predstavlja vodikov atom, u obliku baze ili adicijske soli s kiselinom ili s bazom.
Compounds according to either of the preceding claims, characterized in that R3 represents a group -CO2R4, with R4 representing a hydrogen atom, in the form of a base or of an addition salt with an acid or with a base. 
Spojevi u skladu s bilo kojim od prethodnih zahtjeva, naznačeni time da R3 predstavlja skupinu -CO2R4, gdje R4 predstavlja vodikov atom, u obliku baze ili adicijske soli s kiselinom ili s bazom.
Compounds according to one of the preceding claims, characterized in that X represents a fluorine atom, in the form of a base or of an addition salt with an acid or with a base. 
Spojevi prema jednom od prethodnih zahtjeva, naznačeni time da X predstavlja fluorov atom, u obliku baze ili adicijske soli s kiselinom ili s bazom.
Compounds according to one of Claims 1 to 4, characterized in that: 
Spojevi prema jednom od zahtjeva 1 do 4, naznačeni time da:
Compounds according to one of Claims 1 to 5, characterized in that R is located in the meta or para position, in the form of a base or of an addition salt with an acid or with a base. 
Spojevi prema jednom od zahtjeva 1 do 5, naznačeni time da se R nalazi u meta ili para položaju, u obliku baze ili adicijske soli s kiselinom ili s bazom.
R represents a hydrogen atom, 
R predstavlja vodikov atom,
represents a group -CONH*, where the asterisk * indicates the site of linkage of L, firstly, with the monomer unit M1 and, secondly, with the monomer unit M2, in the form of a base or of an addition salt with an acid or with a base. 
predstavlja skupinu -CONH*, gdje zvjezdica * označava mjesto spajanja L, prvo, s monomernom jedinicom M1, te zatim, s monomernom jedinicom M2, u obliku baze ili adicijske soli s kiselinom ili s bazom.
Compound according to Claim 1, in which R is a linear or branched alkyl group containing from 2 to 3 carbon atoms. 
Spoj prema zahtjevu 1, naznačen time, da R je linearna ili razgranata alkil-skupina koja sadrži od dva do tri atoma ugljika.
Compound according to Claim 1, in which R, Y, p and the position of the group are represented in the following table: Compound R 
Spoj prema zahtjevu 1, naznačen time, da su R, Y i p te pozicija sljedeće skupine: [image], predstavljeni u sljedećoj tablici:
R has the meaning described above, and A represents an anionic residue of a mineral or organic acid, 
R ima značenje koje je gore opisano, dok A predstavlja anionski ostatak mineralne ili organske kiseline, i spoja sljedeće formule B:
the subsequent hydrolysis of the ester obtained from reaction (1). 
naknadna hidroliza estera koji je dobiven iz reakcije u koraku (1).
Preparation process according to Claim 15, in which the said residue A is chosen from the group comprising halide, phosphate, sulfate, nitrate and organic carboxylate. 
Proizvodni postupak prema zahtjevu 15, naznačen time, da je navedeni ostatak A odabran iz skupine koju čine halid, fosfat, sulfat, nitrat i organski karboksilat.
Preparation process according to Claim 16, in which the said residue A is chosen from the group comprising chloride, bromide and iodide. 
Proizvodni postupak prema zahtjevu 16, naznačen time, da je navedeni ostatak A odabran iz skupine koju čine klorid, bromid i jodid.
Preparation process according to Claim 15, in which the said residue X is chosen from the group comprising chloride, bromide and iodide. 
Proizvodni postupak prema zahtjevu 15, naznačen time, da je navedeni ostatak X odabran iz skupine koju čine klorid, bromid i jodid.
Preparation process according to Claim 20, in which the said organic solvent is chosen from the group comprising acetone, methyl ethyl ketone, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide, dioxane and acetonitrile. 
Proizvodni postupak prema zahtjevu 20, naznačen time, da je navedeno organsko otapalo odabrano iz skupine koju čine aceton, metiletilketon, tetrahidrofuran, dimetilformamid, dimetilsulfoksid, dioksan i acetonitril.
Use of a compound according to Claim 24, for preparing a pharmaceutical composition for treating neuropathic pain caused by diabetes, cancer, immunodeficiency, trauma, ischemia, multiple sclerosis, sciatica, trigeminal neuralgia and post-herpetic syndrome. 
Uporaba spoja prema zahtjevu 24, naznačena time, da je za proizvodnju farmaceutskog sastava za liječenje neuropatskih bolova koji su uzrokovani sljedećim stanjima: dijabetes, rak, imunološka deficijencija, ozljeda, ishemija, multipla skleroza, išijas, trigeminalna neuralgija i postherpetični sindrom.
The compound or salt thereof for use of Claim 9, wherein the cancer is basal sub-type breast cancer or a luminal B sub-type breast cancer. 
Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je rak bazalni podtip raka dojke ili luminalni B podtip raka dojke.
The compound or salt thereof for use of Claim 9, wherein the cancer is basal sub-type breast cancer that is ER, HER2 and PR negative breast cancer. 
Spoj, ili njegova sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što je rak bazalni podtip raka dojke koji je ER, HER2 i PR negativan rak dojke.
moving means (12) adapted to generate vibrations of the vessel; 
pokretna sredstva (12) prilagođena za stvaranje vibracija posude;
The polypeptide according to any one of claims 1 to 9, for use with one or more chemotherapeutic agents effective in treating tuberculosis. 
Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je namijenjen upotrebi uz jedno ili više kemoterapijskih sredstava djelotvornih u liječenju tuberkuloze.
The polynucleotide according to any one of claims 11 to 19, for use with one or more chemotherapeutic agents effective in treating tuberculosis. A pharmaceutical composition comprising: 
Polinukleotid u skladu s bilo kojim od patentnih zahtjeva 11 do 19, naznačen time što je namijenjen upotrebi uz jedno ili više kemoterapijskih sredstava djelotvornih u liječenju tuberkuloze.
a polynucleotide comprising a nucleic acid sequence encoding the polypeptide of (a); and 
polinukleotid koji sadrži nukleinskokiselinski slijed koji kodira polipeptid iz (a); i
a pharmaceutically acceptable carrier or excipient, for use in the treatment of latent tuberculosis. 
farmaceutski prihvatljiv nosač ili pomoćnu tvar, namijenjen upotrebi u liječenju latentne tuberkuloze.
Paper strip (1) for determining Minimum Inhibitory Concentration of antibiotics, characterized by the fact that, it is made from paper being permeable to air, it prevents air bubbles from forming at the point of contact with the microbial culture medium (3) that could invalidate the test or render it inaccurate and that it has a predetermined concentration gradient of antibacterial agent graded on a scale of fifteen dilution intervals. 
Papirna traka (1) za određivanje minimalne inhibicijske koncentracije antibiotika, naznačena time što: načinjena je od papira koji propušta zrak, sprječava stvaranje mjehurića zraka na mjestu kontakta s medijem s mikrobnom kulturom (3) koji bi mogli invalidirati test ili ga učiniti netočnim, te što sadrži zadani koncentracijski gradijent antibakterijskog sredstva, graduiran na skali od petnaest intervala razrjeđivanja.
Paper strip (1) for determining Minimum Inhibitory Concentration of antibiotics according to claim 1, characterized by the fact that the aforementioned paper strip (1) on initial contact with the microbial culture medium (3) begins to release the antibiotics with which it is impregnated very slowly and gradually facilitating the user should the strip require repositioning on the microbial culture medium (3). 
Papirna traka (1) za određivanje minimalne inhibicijske koncentracije antibiotika u skladu s patentnim zahtjevom 1, naznačena time što gore navedena papirna traka (1) prilikom prvog kontakta s medijem s mikrobnom kulturom (3) počinje otpuštati antibiotike kojima je natopljena vrlo polako i postupno, što omogućuje da korisnik po potrebi premjesti traku na mediju s mikrobnom kulturom (3).
Combination of green tea extract and pomegranate extract for use for the prevention or reduction of the progression of prostate cancer. 
Kombinacija ekstrakta zelenog čaja i ekstrakta nara, naznačena time što je namijenjena upotrebi u sprječavanju ili usporavanju napredovanja raka prostate.
Combination for use according to claim 1 or 2, as a dietary supplement. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačena time što služi kao dodatak ishrani.
Combination for use according to claim 1 or 2, further comprising co-enzymes, mineral substances, antioxidants, vitamins and agents useful for treating prostate cancer. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačena time što dodatno sadrži koenzime, mineralne tvari, antioksidanse, vitamine i sredstva korisna u liječenju raka prostate.